How GLP-1 Drug Dulaglutide Slows Stomach Emptying and Affects Other Medications

Combined PK modeling predicts how dulaglutide's delay of gastric emptying affects the absorption and blood levels of other oral medications.

Posada, Maria M et al.·CPT: pharmacometrics & systems pharmacology·2025·Moderate Evidencecomputational
RPEP-13091ComputationalModerate Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
computational
Evidence
Moderate Evidence
Sample
N=N/A (modeling study using existing clinical data)
Participants
Healthy participants and patients with type 2 diabetes (from source clinical studies)

What This Study Found

A combined PopPK/PBPK model accurately predicts how dulaglutide-induced gastric emptying delay affects oral drug absorption and pharmacokinetics.

Key Numbers

Model verified against clinical DDI data at low dulaglutide doses; predicted changes in AUC, Cmax, and tmax of co-administered drugs at higher doses.

How They Did This

Combined population pharmacokinetic and physiologically-based pharmacokinetic modeling validated against clinical study data.

Why This Research Matters

Patients on GLP-1 drugs often take multiple medications — predicting drug interactions computationally saves time and money versus running new clinical trials.

The Bigger Picture

This modeling approach could be applied to predict drug interactions for any GLP-1 drug, not just dulaglutide.

What This Study Doesn't Tell Us

Model predictions require validation for each specific drug combination. May not capture all patient-specific variability.

Questions This Raises

  • ?Which commonly co-administered medications are most affected by GLP-1 gastric delay?
  • ?Can this model be applied to semaglutide and tirzepatide?

Trust & Context

Key Stat:
Combined model PopPK + PBPK approach predicts drug-drug interactions from GLP-1-induced gastric emptying delay
Evidence Grade:
Computational modeling validated against clinical data — strong predictive framework but each drug interaction needs individual validation.
Study Age:
Published in 2025, providing a modern modeling tool for GLP-1 drug interaction prediction.
Original Title:
A Combined Modeling Approach to Predict the Effect of Gastric Emptying Delay on the Pharmacokinetics of Small Molecules.
Published In:
CPT: pharmacometrics & systems pharmacology, 14(12), 2026-2039 (2025)
Database ID:
RPEP-13091

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Do GLP-1 drugs affect other medications?

Yes — by slowing stomach emptying, GLP-1 drugs can change how quickly other oral medications are absorbed, potentially affecting their effectiveness.

Should I adjust my other medications when starting a GLP-1 drug?

This study provides a modeling framework to predict which drugs may be affected. Always discuss your full medication list with your doctor.

Read More on RethinkPeptides

Cite This Study

RPEP-13091·https://rethinkpeptides.com/research/RPEP-13091

APA

Posada, Maria M; Schneck, Karen B; Morse, Bridget L; Rougee, Luc R A; Tham, Lai San; Rehmel, Jessica F; Thompson, Brian; Stamatis, Stephen D; Hall, Stephen D; Dickinson, Gemma L. (2025). A Combined Modeling Approach to Predict the Effect of Gastric Emptying Delay on the Pharmacokinetics of Small Molecules.. CPT: pharmacometrics & systems pharmacology, 14(12), 2026-2039. https://doi.org/10.1002/psp4.70101

MLA

Posada, Maria M, et al. "A Combined Modeling Approach to Predict the Effect of Gastric Emptying Delay on the Pharmacokinetics of Small Molecules.." CPT: pharmacometrics & systems pharmacology, 2025. https://doi.org/10.1002/psp4.70101

RethinkPeptides

RethinkPeptides Research Database. "A Combined Modeling Approach to Predict the Effect of Gastri..." RPEP-13091. Retrieved from https://rethinkpeptides.com/research/posada-2025-a-combined-modeling-approach

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.